Faculty: Samir Taneja, MD, Wei Phin Tan, MD, Peter Carroll, MD

Moderator: Laurence Klotz, MD and Tom Polascik, MD

Samir Taneja, MD

Samir S. Taneja, MD is the James M. and Janet Riha Neissa Professor of Urologic Oncology; Professor of Urology, Radiology, and Biomedical Engineering; GU Program Leader in the Perlmutter Cancer Center; Director of the Division of Urologic Oncology, and Vice Chair in the Department of Urology at NYU Langone Health. Dr. Taneja is nationally renowned as a key opinion leader in the treatment and research of prostate cancer. Over the past decade, his clinical research interest has been in prostate cancer diagnostics, with particular focus on the application of imaging in the detection, risk stratification, and surgical therapy of prostate cancer.   He has pioneered the clinical application of pre-biopsy prostate MRI and techniques of MRI-targeted biopsy, and is widely recognized as an innovator in the emerging field of prostate cancer focal therapy. His previous laboratory research has focused in androgen receptor transcriptional activation and the relationship of AR to prostate cancer growth, for which he has received funding through the National Institutes of Health, Department of Defense, and the Prostate Cancer Foundation. 

Dr. Taneja has previously served on the ABU Examination Committee, the SUO Oncology Knowledge Assessment Test Committee, the Society of Urologic Oncology Board of Directors, and he is previous Secretary General and past-President of the Urologic Research Society. He is an oral examiner for the American Board of Urology and an elected member of the American Association of Genitourinary Surgeons. He has authored over 250 articles, 25 book chapters, and 5 textbooks.  He is the Urology Surveys prostate cancer contributor for the Journal of Urology, previous Consulting Editor of the Urologic Clinics of North America, and Editor of the 3rd, 4th, and 5th, editions of Taneja's Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology. 

Wei Phin Tan, MD

Dr. Wei Phin Tan, M.D. is an Assistant Professor of Urology at MD Anderson at Cooper.

Dr Tan’s research interest focuses on malignancies of the genitourinary system, with a particular emphasis on (i) prostate cancer diagnostics, (ii) focal therapy for prostate cancer, (iii) robotic assisted surgery (prostatectomies, nephrectomies, partial nephrectomies, cystectomies with intracorporeal reservoirs, retroperitoneal lymph node dissection), and (iv) hyperthermia and heat-targeted therapy.

Dr Tan has published more than 50 peer reviewed publications and delivered more than international/national presentations to date. He was also previously funded by the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant from the National Cancer Institute (NCI). 

Peter Carroll, MD, MPH

Dr. Peter Carroll is Professor of Urology and holds the Ken and Donna Derr-Chevron and Taube Family Distinguished Professorships at UCSF. He is a member of the UCSF Helen Diller Family Comprehensive Cancer Center and an expert in managing urologic cancers.

In research, Carroll’s areas of interest include innovative methods of urinary tract reconstruction, refinement of robotic prostatectomy, development of biomarkers that predict cancer aggressiveness, the use of active surveillance rather than immediate treatment for prostate cancer and how cancer detection and treatment impact quality of life. He has received many honors and awards, published more than 600 articles on cancer detection and treatment and is principal investigator or co-investigator of many peer-reviewed research grants.

Carroll graduated with honors from Georgetown University School of Medicine and came to UCSF for general surgery training and a residency in urology. He completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center before returning to UCSF. He received his MPH from the University of California at Berkeley.

Laurence Klotz, CM, MD, FRCSC

Dr. Laurence Klotz was educated at the University of Toronto, Canada, where in 1977 he obtained his MD. Dr. Klotz completed his residency at the University of Toronto in 1983. Subsequently, he was a Fellow in Uro-Oncology and Tumor Biology at the Memorial Sloan Kettering Cancer Center in New York, completing it in 1985.

Dr. Klotz then returned to Sunnybrook Health Sciences Centre in Toronto. He is an Associate Scientist at the Sunnybrook Research Institute, past Chief of Urology, Professor of Surgery at the University of Toronto, and the Sunnybrook Chair of Prostate Cancer Research.

Dr. Klotz is a widely published uro-oncologist (504 peer review publications, 6 books). His basic research interests have included research in the role of micronutrients and diet in prostate cancer prevention, and translational research in biomarkers and imaging. His research lab has been active for 30 years, producing several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image guided therapy, molecular biomarkers, and androgen receptor targeted therapy. He has led numerous randomized trials in prostate cancer.

Active surveillance was a concept pioneered under Dr. Klotz’s leadership. He led the team at Sunnybrook who was the first to implement an approach to patients with low risk prostate cancer based on conservative management, with selective intervention for those patients who were diagnosed as higher risk over time. He coined the term ‘active surveillance’, and was responsible for promoting its acceptance by urological and radiation oncology communities worldwide. His drive to reduce the overtreatment, morbidity, and mortality of prostate cancer has led to over a hundred papers on this subject alone and numerous national and international invitations as a guest lecturer and visiting professor.

In addition to his basic and clinical research endeavors, Dr. Klotz has initiated and participated in many professional organizations and societies. In 1994, he founded the Canadian Journal of Urology, which was the officially endorsed journal of the Canadian Urological Association from 1996 to 2004. In 2005 he founded the Canadian Urology Association Journal in conjunction with the CUA, was Editor in Chief until 2010, and currently is the CUAJ Editor Emeritus. He has been Associate Editor of the Journal of Urology (Prostate Cancer) since 2014. Since 2018 he has been the Managing Editor of the International Consultations on Urologic Diseases, and in 2020 this re-invigorated initiative produced the book ‘Molecular Biomarkers in Urologic Oncology’ under his leadership.

Dr. Klotz established and chaired the Canadian Urology Consortium (CURC), a clinical research network, in 2000 and the World Urologic Oncology Federation (WUOF), which brought the world’s regional and national Uro Oncology Societies together under one umbrella in 2002. Originally 6, there are now 20 member societies.

Dr. Klotz was awarded the Queen’s Jubilee Medal in 2013 for meritorious public service, and the University of Toronto Department of Surgery Lister Prize for outstanding research contributions and the Society of Urologic Oncology Medal in 2014.

In 2015 he received Canada’s highest civilian award, the Order of Canada, and the Harold Warwick Prize from the Canadian Cancer Society for international contributions to cancer control. The AUA presented him the Richard Williams Award for outstanding contributions in urologic oncology in 2016. He has received Lifetime Achievement Awards from the University of Toronto in 2017 and the Canadian Urological Association in 2019. He also received the Huggins medal from the SUO in 2019.

Dr. Klotz is married to Ursula, and has 2 children, Alex, a professor of physics at California State in Los Angeles, and Betsy, a recreational therapist. He founded ‘The Void’, an all-Urology Band in which he plays piano. He has never received any awards for his tennis or ice hockey performance, both of which he plays frequently.